IB Pharmaceuticals Inc (INNT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:IB Pharmaceuticals Inc (INNT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8131
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
IB Pharmaceuticals Inc (IB Pharmaceuticals), formerly Innovate Biopharmaceuticals Inc, is a clinical-stage biotechnology company that discovers and develops novel medicines for orphan and gastroenterological disorders. The company’s pipeline includes INN-108 intended for inflammatory bowel disorders, ulcerative colitis and GI orphan disease; INN-202 intended for the treatment of celiac disease; INN-217 intended for nonalcoholic steatohepatitis; INN-289 intended for Crohn’s disease; and INN-329 intended for magnetic resonance cholangiopancreatography. The company holds and operates its patents across the US, Japan and other countries. IB Pharmaceuticals is headquartered in Raleigh, North Carolina, the US.

IB Pharmaceuticals Inc (INNT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Innovate Biopharma Acquires Assets Related to RG-1068 from Repligen 11
Venture Financing 12
Innovate Biopharma Raises USD1.5 Million in Venture Financing 12
Innovate Biopharma Raises USD1.4 Million in Venture Financing 13
Innovate Biopharma Raises USD2.7 Million in Venture Financing 14
Partnerships 15
Innovate Biopharma Enters into Agreement with Amarex Clinical Research 15
IB Pharma Enters into Agreement with University of Virginia School of Medicine 16
Innovate Biopharma Enters into R&D Agreement with University of Maryland School of Medicine 17
Merger 18
Monster Digital Completes Reverse Merger Transaction with Innovate Biopharma 18
Licensing Agreements 20
Innovate Biopharm Enters into Licensing Agreement with Alba Therapeutics 20
Equity Offering 21
IB Pharma Plans to Raise up to USD175 Million in Public Offering of Shares 21
IB Pharma Plans to Raise Funds through Public Offering of Shares 22
IB Pharma Raises USD23.5 Million in Private Placement of Securities 23
Debt Offering 24
IB Pharma Raises USD4.8 Million in Private Placement of Debt Securities 24
IB Pharmaceuticals Inc – Key Competitors 25
IB Pharmaceuticals Inc – Key Employees 26
IB Pharmaceuticals Inc – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Financial Announcements 28
Aug 15, 2018: Innovate Biopharmaceuticals announces second quarter 2018 financial results 28
May 16, 2018: Innovate Biopharmaceuticals Reports First Quarter 2018 Key Financial and Corporate Highlights 29
Corporate Communications 30
Jun 13, 2018: Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of Anna Kazanchyan, M.D. 30
Mar 13, 2018: Innovate Biopharmaceuticals Names June Almenoff As Chief Operating Officer And Chief Medical Officer 31
Product Approvals 32
Sep 06, 2017: Innovate Biopharmas Pediatric Ulcerative Colitis Drug Granted FDA Orphan Designation 32
Jul 12, 2017: Innovate Biopharmaceuticals Submits Orphan Drug Application to FDA for Pediatric Ulcerative Colitis Indication 33
Clinical Trials 34
Feb 21, 2017: Innovate Biopharmaceuticals To Highlight Its Late-Stage Product Pipeline Targeting Celiac Disease And Ulcerative Colitis At The Cowen Healthcare Conference On March 6, 2017 34
Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on INN-108 Phase 2 Trial 35
Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on larazotide acetate (INN-202) 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IB Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Innovate Biopharma Acquires Assets Related to RG-1068 from Repligen 11
Innovate Biopharma Raises USD1.5 Million in Venture Financing 12
Innovate Biopharma Raises USD1.4 Million in Venture Financing 13
Innovate Biopharma Raises USD2.7 Million in Venture Financing 14
Innovate Biopharma Enters into Agreement with Amarex Clinical Research 15
IB Pharma Enters into Agreement with University of Virginia School of Medicine 16
Innovate Biopharma Enters into R&D Agreement with University of Maryland School of Medicine 17
Monster Digital Completes Reverse Merger Transaction with Innovate Biopharma 18
Innovate Biopharm Enters into Licensing Agreement with Alba Therapeutics 20
IB Pharma Plans to Raise up to USD175 Million in Public Offering of Shares 21
IB Pharma Plans to Raise Funds through Public Offering of Shares 22
IB Pharma Raises USD23.5 Million in Private Placement of Securities 23
IB Pharma Raises USD4.8 Million in Private Placement of Debt Securities 24
IB Pharmaceuticals Inc, Key Competitors 25
IB Pharmaceuticals Inc, Key Employees 26

List of Figures
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IB Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[IB Pharmaceuticals Inc (INNT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Morinaga & Co., Ltd. (2201):企業の財務・戦略的SWOT分析
    Morinaga & Co., Ltd. (2201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Berner Oberland-Bahnen AG:企業の戦略・SWOT・財務情報
    Berner Oberland-Bahnen AG - Strategy, SWOT and Corporate Finance Report Summary Berner Oberland-Bahnen AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Kuwait Projects Company Holding KSC (KPROJ):企業の財務・戦略的SWOT分析
    Kuwait Projects Company Holding KSC (KPROJ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Little Caesar Enterprises Inc:企業の戦略・SWOT・財務分析
    Little Caesar Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Little Caesar Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Medicago Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Medicago Inc (Medicago), a subsidiary of Mitsubishi Tanabe Pharma Corp is a clinical-stage biotechnology company that develops and produces vaccines and antibodies. The company concentrates on the discovery and development of novel vaccines and therapeutic proteins for infectious diseases. I …
  • Petrol dd Ljubljana (PETG):企業の財務・戦略的SWOT分析
    Petrol dd Ljubljana (PETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Intershop Communications AG (ISH2):企業の財務・戦略的SWOT分析
    Summary Intershop Communications AG (Intershop), formerly NetConsult GmbH, is an information technology company that develops and offers integrated e-commerce solutions. The company provides services such as omni-channel management, experience management, product information management, marketing an …
  • First Republic Private Wealth Management:企業の戦略・SWOT・財務情報
    First Republic Private Wealth Management - Strategy, SWOT and Corporate Finance Report Summary First Republic Private Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • United Food Holdings Limited:戦略・SWOT・企業財務分析
    United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • LipimetiX Development Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary LipimetiX Development Inc (LipimetiX), formerly LipimetiX LLC is a biopharmaceutical company that develops drugs to treat refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases. The company develops drugs based on chimeri …
  • Crane Co (CR):企業の財務・戦略的SWOT分析
    Crane Co (CR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • ArQule Inc (ARQL)-製薬・医療分野:企業M&A・提携分析
    Summary ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including …
  • Service Corporation International:企業の戦略・SWOT・財務情報
    Service Corporation International - Strategy, SWOT and Corporate Finance Report Summary Service Corporation International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Anadarko Petroleum Corp (APC):企業の財務・戦略的SWOT分析
    Anadarko Petroleum Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • United Technologies Corp (UTX):電力:M&Aディール及び事業提携情報
    Summary United Technologies Corp (UTC) is a provider of technology products and services for applications in the aerospace and building systems industries. The company’s building systems portfolio includes elevators and escalators, moving walkways, heating, ventilating, air conditioning (HVAC) and r …
  • Allergy Therapeutics Plc (AGY):企業の財務・戦略的SWOT分析
    Allergy Therapeutics Plc (AGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Madrigal Pharmaceuticals Inc (MDGL):企業の財務・戦略的SWOT分析
    Madrigal Pharmaceuticals Inc (MDGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Yes Bank Ltd:企業のM&A・事業提携・投資動向
    Yes Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Yes Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Tandem Diabetes Care Inc (TNDM):企業の製品パイプライン分析2018
    Summary Tandem Diabetes Care Inc (Tandem) is a medical device company that designs, develops and manufactures diabetic care products. The company provides products such as t:slim X2 insulin pump, t:slim G4 insulin pump, t:flex insulin pump, t:simulator demo app, software and apps, t:connect applicat …
  • Tata Teleservices (Maharashtra) Ltd (TTML):企業の財務・戦略的SWOT分析
    Tata Teleservices (Maharashtra) Ltd (TTML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆